Concepedia

Martin Šimkovič

MŠ

Statistics

Publications

53

Citations

3.8K

H-Index

24

Active since

2012

Affiliations

University Hospital Hradec Králové(Current)

Charles University

St James's University Hospital

Vita-Salute San Raffaele University

Medical University of Lodz

Martin Šimkovič is an author at University Hospital Hradec Králové specializing in chronic lymphocytic leukemia therapy, medicine, and oncology.

ORCID

Publications per year

2012–2025

53

Publications

53

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology · 2018 · 548 citations

, , +13

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen et al. · New England Journal of Medicine · 2022 · 457 citations · Full text

, , +16

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 362 citations · Full text

, , +14

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl et al. · The Lancet Oncology · 2022 · 278 citations · Full text

, , +8

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin et al. · Leukemia · 2020 · 275 citations · Full text

, , +10

1–5 of 53